// App-Quantinova.ai

THU0290 (2018) : Effects of biologic dmards on physical function in patients with active psoriatic arthritis: results of network meta-analyses

Researchers

Presenter

  • A. Ruyssen-Witrand

Principal Investigators

  • C. Sapin

  • S. Hartz

  • S. Liu Leage

Medical Centers

  • Rheumatology Center, Purpan Teaching Hospital, Toulouse

  • Eli Lilly and Company, Paris, France

  • Eli Lilly and Company, Erl Wood, UK

Locations

  • France

  • United Kingdom

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

  • secukinumab

  • Ustekinumab

  • Adalimumab

  • Apremilast

  • Infliximab

  • Etanercept

  • CHS-0214

  • LY2439821

  • golimumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved